Comparison of lead bioavailability in F344 rats fed lead acetate, lead oxide, lead sulfide, or lead ore concentrate from Skagway, Alaska.
An animal model using rats was developed to initiate investigations on the bioavailability of different sources of environmental lead. Lead must be absorbed and transported to target organs like brain, liver, kidney, and bone, before susceptible cells can be harmed. The bioavailability and therefore the toxicity of lead are dependent upon the route of exposure, dose, chemical structure, solubility, particle size, matrix incorporation, and other physiological and physicochemical factors. In the present study male F344 rats were fed < or = 38 microns size particles of lead sulfide, lead oxide, lead acetate, and a lead ore concentrate from Skagway, Alaska, mixed into the diet at doses of 0, 10, 30, and 100 ppm as lead for 30 d. No mortality or overt symptoms of lead toxicity were observed during the course of the study. Maximum blood lead concentrations attained in the 100 ppm groups were approximately 80 micrograms/dl in rats fed lead acetate and lead oxide, and were approximately 10 micrograms/dl in those fed lead sulfide and lead ore concentrate. Maximum bone lead levels in rats fed soluble lead oxide and lead acetate were much higher (approximately 200 micrograms/g) than those seen in rats fed the less soluble lead sulfide and lead ore (approximately 10 micrograms); kidney lead concentrations were also about 10-fold greater in rats fed the more soluble compared to the less soluble lead compounds. However, strong correlations between dose and tissue lead concentrations were observed in rats fed each of the four different lead compounds. Kidney lesions graded as minimal occurred in 7/10 rats fed 30 ppm and in 10/10 rats fed 100 ppm lead acetate, but not at lower doses or from other lead compounds. Similarly, urinary aminolevulinic acid excretion, a biomarker for lead toxicity, was increased in rats fed 100 ppm lead acetate or lead oxide, but was unaffected at lower doses or by the less soluble lead compounds. Although the histological and biochemical responses to lead toxicity were restricted to the more soluble lead compounds in this study, lead from Skagway lead ore concentrate and lead sulfide was also bioavailable, and accumulated in proportion to dose in vulnerable target organs such as bone and kidney. Longer-term studies with different mining materials are being conducted to determine if tissue lead continues to increase, and whether the levels attained are toxic. Data from such studies can be used to compare the toxicity and bioavailability of lead from different sources in the environment.
Dieter
M P
MP
National Institute of Environmental Health Sciences, Research Triangle Institute, NC 27709.
Matthews
H B
HB
Jeffcoat
R A
RA
Moseman
R F
RF
D000284:Administration, Oral; D000413:Alaska; D000818:Animals; D001682:Biological Availability; D001842:Bone and Bones / Q000737:chemistry; D004781:Environmental Exposure; D007408:Intestinal Absorption; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology; D007854:Lead / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D008297:Male; D008906:Mining; D009942:Organometallic Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D010087:Oxides / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D051381:Rats; D011916:Rats, Inbred F344; D013440:Sulfides / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D014018:Tissue Distribution
D009942:Organometallic Compounds; D010087:Oxides; D013440:Sulfides; C018391:lead sulfide; D007854:Lead; C047365:lead oxide; C008261:lead acetate